Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Lyra Therapeutics Inc (LYRA)

Lyra Therapeutics Inc (LYRA)
0.1079 x 4 0.1100 x 56
Post-market by (Cboe BZX)
0.1050 +0.0059 (+5.95%) 04/25/25 [NASDAQ]
0.1079 x 4 0.1100 x 56
Post-market 0.1080 +0.0030 (+2.86%) 19:59 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.0991
Day High
0.1055
Open 0.0991
Previous Close 0.0991 0.0991
Volume 1,261,800 1,261,800
Avg Vol 1,774,520 1,774,520
Stochastic %K 43.69% 43.69%
Weighted Alpha -76.62 -76.62
5-Day Change +0.0185 (+21.39%) +0.0185 (+21.39%)
52-Week Range 0.0820 - 5.6500 0.0820 - 5.6500
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,529
  • Shares Outstanding, K 65,881
  • Annual Sales, $ 1,530 K
  • Annual Income, $ -93,440 K
  • EBIT $ -96 M
  • EBITDA $ -98 M
  • 60-Month Beta 0.04
  • Price/Sales 3.98
  • Price/Cash Flow N/A
  • Price/Book 0.52
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.98
  • Most Recent Earnings $-0.16 on 03/13/25
  • Next Earnings Date 04/29/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 725.78% ( +67.80%)
  • Historical Volatility 110.28%
  • IV Percentile 95%
  • IV Rank 62.71%
  • IV High 1,087.61% on 08/21/24
  • IV Low 117.25% on 10/11/24
  • Put/Call Vol Ratio 0.06
  • Today's Volume 18
  • Volume Avg (30-Day) 76
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 3,057
  • Open Int (30-Day) 4,730

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.15
  • Number of Estimates 2
  • High Estimate -0.15
  • Low Estimate -0.15
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +57.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0820 +28.05%
on 04/09/25
Period Open: 0.1564
0.1633 -35.70%
on 03/26/25
-0.0514 (-32.86%)
since 03/25/25
3-Month
0.0820 +28.05%
on 04/09/25
Period Open: 0.1876
0.2218 -52.66%
on 02/24/25
-0.0826 (-44.03%)
since 01/24/25
52-Week
0.0820 +28.05%
on 04/09/25
Period Open: 5.1700
5.6500 -98.14%
on 05/01/24
-5.0650 (-97.97%)
since 04/25/24

Most Recent Stories

More News
Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

LYRA : 0.1050 (+5.95%)
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

LYRA : 0.1050 (+5.95%)
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

LYRA : 0.1050 (+5.95%)
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company, Lyra or Lyra Therapeutics), a clinical-stage therapeutics company leveraging its...

LYRA : 0.1050 (+5.95%)
LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage therapeutics company leveraging its proprietary XTreoâ„¢ platform...

LYRA : 0.1050 (+5.95%)
Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA)("Lyra" or the "Company"), a clinical-stage therapeutics company leveraging its proprietary XTreoâ„¢...

LYRA : 0.1050 (+5.95%)
Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreoâ„¢ platform to enable precise,...

LYRA : 0.1050 (+5.95%)
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Lyra Therapeutics, Inc. (NASDAQ: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreoâ„¢ platform to enable precise,...

LYRA : 0.1050 (+5.95%)
Lyra Therapeutics to Highlight LYR-210 and LYR-220 Clinical Programs at Virtual Event with Leading Clinical CRS Experts

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreoâ„¢ platform to enable precise,...

LYRA : 0.1050 (+5.95%)
Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology

LYR-210 is the First Drug-Eluting Product Candidate to Demonstrate Statistically Significant Symptom Improvement for Six Months with a Single Administration in Surgically Naïve Chronic Rhinosinusitis...

LYRA : 0.1050 (+5.95%)

Business Summary

Lyra Therapeutics Inc. is a clinical-stage therapeutics company. It is focused on the development and commercialization of novel integrated drug and delivery solutions for patients with ear, nose and throat diseases. The company's proprietary technology platform, XTreo(TM), is designed to precisely and...

See More

Key Turning Points

3rd Resistance Point 0.1137
2nd Resistance Point 0.1096
1st Resistance Point 0.1073
Last Price 0.1050
1st Support Level 0.1009
2nd Support Level 0.0968
3rd Support Level 0.0945

See More

52-Week High 5.6500
Fibonacci 61.8% 3.5230
Fibonacci 50% 2.8660
Fibonacci 38.2% 2.2090
Last Price 0.1050
52-Week Low 0.0820

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective